{"id":"18f-psma-1007","safety":{"commonSideEffects":[{"rate":null,"effect":"Radiation exposure (inherent to PET imaging)"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This radiopharmaceutical is a PSMA-targeting agent conjugated with the positron-emitting isotope fluorine-18, enabling PET imaging to detect and localize PSMA-positive lesions in prostate cancer and other malignancies. The compound binds with high affinity to PSMA, a transmembrane glycoprotein overexpressed in prostate cancer cells, allowing visualization of tumor burden and metastatic disease.","oneSentence":"18F-PSMA-1007 is a fluorine-18 labeled small molecule that binds to prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of PSMA-expressing tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:44:11.255Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"PET imaging of PSMA-positive prostate cancer"},{"name":"Detection of metastatic prostate cancer lesions"}]},"trialDetails":[{"nctId":"NCT07089550","phase":"","title":"PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2025-04-02","conditions":"PSMA Positive Tumors or Tumor Tissues, Prostate Cancer Metastatic","enrollment":1300},{"nctId":"NCT07386496","phase":"NA","title":"The Role of 18F-PSMA PET in Prostate Cancer Diagnosis in Equivocal MRI","status":"NOT_YET_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-03-01","conditions":"Prostate Cancer","enrollment":250},{"nctId":"NCT06122584","phase":"PHASE3","title":"Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer","status":"RECRUITING","sponsor":"ABX advanced biochemical compounds GmbH","startDate":"2024-06-13","conditions":"Prostate Cancer","enrollment":380},{"nctId":"NCT06881823","phase":"PHASE1, PHASE2","title":"Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2026-06-29","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT07258056","phase":"NA","title":"GUidance In Prostate Cancer DEtection With 18F-PSMA-1007-PET/MRI and Targeted Biopsies","status":"RECRUITING","sponsor":"Mads Ryo Jochumsen","startDate":"2025-11-03","conditions":"Prostate Cancer","enrollment":100},{"nctId":"NCT05520255","phase":"PHASE3","title":"18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2023-07-25","conditions":"Prostate Cancer","enrollment":2800},{"nctId":"NCT04742361","phase":"PHASE3","title":"Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer","status":"COMPLETED","sponsor":"ABX advanced biochemical compounds GmbH","startDate":"2021-08-27","conditions":"Prostate Cancer, Prostate Cancer Recurrent","enrollment":136},{"nctId":"NCT05534594","phase":"NA","title":"Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2022-08-19","conditions":"Medullary Thyroid Cancer, Medullary Thyroid Carcinoma, Thyroid Carcinoma, Medullary","enrollment":8},{"nctId":"NCT05712174","phase":"PHASE2","title":"A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2023-09-14","conditions":"Oncology, Prostate Cancer","enrollment":176},{"nctId":"NCT05815316","phase":"PHASE2","title":"18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer","status":"WITHDRAWN","sponsor":"IRCCS San Raffaele","startDate":"2023-04-30","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT06919159","phase":"","title":"Intratumoral Heterogeneity on [18F]PSMA and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Prostate Cancer","status":"COMPLETED","sponsor":"Jiequn Yu","startDate":"2021-07-01","conditions":"Prostate Cancer (Diagnosis), Prostate-specific Membrane Antigen, Positron Emission Tomography (PET)","enrollment":45},{"nctId":"NCT04794777","phase":"PHASE3","title":"Comparing \"Salvage\" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer","status":"RECRUITING","sponsor":"Stefan Carlsson","startDate":"2018-10-30","conditions":"Prostate Cancer","enrollment":450},{"nctId":"NCT04053842","phase":"PHASE2","title":"Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Glenn Bauman","startDate":"2021-02-04","conditions":"Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm","enrollment":45},{"nctId":"NCT06820333","phase":"","title":"Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer","status":"RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2025-01-10","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":200},{"nctId":"NCT05123300","phase":"NA","title":"PRISMA-PET - Primary Staging of Prostate Cancer With PSMA","status":"TERMINATED","sponsor":"Odense University Hospital","startDate":"2021-10-04","conditions":"Prostate Cancer","enrollment":385},{"nctId":"NCT06723665","phase":"NA","title":"The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Affiliated Hospital of Jiangnan University","startDate":"2024-01-25","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT06657131","phase":"","title":"Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer","status":"RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2024-11-01","conditions":"Prostate Cancer After a Radical Treatment, Biochemical Recurrence of Malignant Neoplasm of Prostate, Biochemical Persistence of Prostate Cancer","enrollment":250},{"nctId":"NCT04487847","phase":"PHASE1, PHASE2","title":"18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2020-09-01","conditions":"Prostate Cancer","enrollment":75},{"nctId":"NCT05709535","phase":"","title":"PSMA-PET/CT Registry","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2023-07-11","conditions":"Prostate Cancer","enrollment":128},{"nctId":"NCT05079828","phase":"NA","title":"Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2022-07-07","conditions":"Prostate Cancer","enrollment":100},{"nctId":"NCT04733768","phase":"PHASE2","title":"18F-PSMA-1007 PET/CT Imaging in Patients with Biochemically Recurrent or High-risk Prostate Cancer","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2021-08-31","conditions":"Prostate Cancer","enrollment":100},{"nctId":"NCT06489496","phase":"","title":"Prostate Cancer 18F-PSMA-1007 PET/CT Access Trial","status":"NOT_YET_RECRUITING","sponsor":"Alberta Health services","startDate":"2024-10-01","conditions":"Prostate Cancer","enrollment":1000},{"nctId":"NCT06428708","phase":"EARLY_PHASE1","title":"[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Western University","startDate":"2022-01-24","conditions":"Metastatic Clear Cell Renal Cell Carcinoma","enrollment":30},{"nctId":"NCT06462495","phase":"EARLY_PHASE1","title":"Head-to-head Comparison of [18F]F-PSMA-N5 With [18F]F-PSMA-1007 PET/CT in PCa Diagnosis, Recurrence, and Metastasis","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-04-10","conditions":"Prostate Cancer, PET/CT","enrollment":30},{"nctId":"NCT04986280","phase":"","title":"Diagnostic Accuracy and Performance of 18F-PSMA-1007","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2021-07-13","conditions":"Prostate Cancer","enrollment":174},{"nctId":"NCT05141760","phase":"PHASE2","title":"18F-PSMA PET and MRI in the Primary Staging of Prostate Cancer Patients","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2022-02-10","conditions":"Prostate Cancer","enrollment":150},{"nctId":"NCT06363435","phase":"","title":"AI-based Measurements of Tumour Burden in PSMA PET-CT","status":"RECRUITING","sponsor":"Elin Tragardh","startDate":"2024-03-29","conditions":"Prostate Cancer","enrollment":1500},{"nctId":"NCT05587192","phase":"NA","title":"Radical Prostatectomy Without Prostate Biopsy Following PSMA PET/CT Based on Diagnostic Model","status":"UNKNOWN","sponsor":"Anhui Provincial Hospital","startDate":"2022-11-10","conditions":"Prostate Cancer","enrollment":57},{"nctId":"NCT04644822","phase":"PHASE3","title":"Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer.","status":"COMPLETED","sponsor":"Centre for Probe Development and Commercialization","startDate":"2020-12-21","conditions":"Prostate Cancer Recurrent, Recurrent Prostate Cancer","enrollment":100},{"nctId":"NCT06219746","phase":"NA","title":"99mTc-MIP-1404 SPECT/CT in Primary Staging of Prostate Cancer","status":"RECRUITING","sponsor":"Turku University Hospital","startDate":"2022-06-01","conditions":"Prostate Cancer","enrollment":320},{"nctId":"NCT05422105","phase":"","title":"Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient","status":"UNKNOWN","sponsor":"Primo Biotechnology Co., Ltd","startDate":"2023-07-01","conditions":"Prostate Cancer, Prostate Neoplasm","enrollment":230},{"nctId":"NCT05448404","phase":"NA","title":"A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma","status":"UNKNOWN","sponsor":"First Hospital of China Medical University","startDate":"2022-03-08","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT03537391","phase":"NA","title":"Novel Imaging in Staging of Primary Prostate Cancer","status":"COMPLETED","sponsor":"Turku University Hospital","startDate":"2018-03-01","conditions":"High Risk Prostate Cancer","enrollment":80},{"nctId":"NCT03187990","phase":"NA","title":"Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA","status":"COMPLETED","sponsor":"Irene Burger","startDate":"2017-03-03","conditions":"Prostate Cancer","enrollment":52},{"nctId":"NCT04102553","phase":"PHASE3","title":"F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence","status":"COMPLETED","sponsor":"ABX advanced biochemical compounds GmbH","startDate":"2019-03-06","conditions":"Prostate Cancer, Prostate Cancer Recurrent","enrollment":200},{"nctId":"NCT03876912","phase":"NA","title":"The Effect of ADT on PSMA Expression in Metastatic Prostate Cancer","status":"UNKNOWN","sponsor":"Turku University Hospital","startDate":"2019-03-01","conditions":"Prostate Cancer","enrollment":35},{"nctId":"NCT04588454","phase":"NA","title":"18F-PSMA PET/CT for Visualization of Glioblastoma Multiforme","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2020-01-17","conditions":"Glioblastoma Multiforme","enrollment":5},{"nctId":"NCT04239742","phase":"NA","title":"F18-PSMA-1007 PET for Early Biochemical Recurrence of Prostate Cancer","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2020-01-02","conditions":"Prostate Cancer Recurrent","enrollment":50},{"nctId":"NCT04159090","phase":"NA","title":"Head- to Head Comparison of [68Ga]Ga-PSMA-11 With [18F]PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as Reference-Standard","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2018-01-15","conditions":"Prostate Cancer","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":149,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["[18F]FPSMA-1007","Fluorine-18 labeled prostate specific membrane antigen","18F-PSMA-1007 injection","Fluorine-18 PSMA 1007"],"phase":"phase_3","status":"active","brandName":"18F-PSMA-1007","genericName":"18F-PSMA-1007","companyName":"Affiliated Hospital of Jiangnan University","companyId":"affiliated-hospital-of-jiangnan-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"18F-PSMA-1007 is a fluorine-18 labeled small molecule that binds to prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of PSMA-expressing tumors. Used for PET imaging of PSMA-positive prostate cancer, Detection of metastatic prostate cancer lesions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}